# Phase II Trial of Ontak With Metastatic Melanoma

Source: https://onco.cc/trials/nct00299689/  
OnCo record `nct00299689` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Denileukin diftitox in Melanoma, run by James Graham Brown Cancer Center, completed.

## Summary

Phase II Trial of Ontak With Metastatic Melanoma is a phase 2 interventional study registered as NCT00299689 by James Graham Brown Cancer Center, with 69 participants recorded, started 2006-03 and reaching its primary completion in 2010-01. Interventions recorded: Denileukin diftitox. Conditions recorded: Malignant Melanoma.

Linked to the drug Denileukin diftitox because the registry names it among its interventions and Melanoma among its conditions. Registry record only: no result has been read by an editor.

## Fields

- Kind: Trial
- Status: completed
- Last checked: 2026-09-22
- Tags: pipeline; ctgov-ingest
- Registry id: NCT00299689
- Phase: 2
- Setting: Phase II Trial of ONTAK With Metastatic Melanoma
- Sponsor: James Graham Brown Cancer Center
- Enrolled: 69

## Sources

- ClinicalTrials.gov NCT00299689: https://clinicaltrials.gov/study/NCT00299689

## Connected records

- cancers: [Melanoma](https://onco.cc/cancers/melanoma/)
- drugs: [Denileukin diftitox](https://onco.cc/drugs/denileukin-diftitox/)

---
JSON: https://onco.cc/api/v1/entities/nct00299689.json